

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

Form 8-K

February 08, 2016

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): February 08, 2016

**THERAPEUTIC SOLUTONS INTERNATIONAL, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Nevada**

(State or other jurisdiction of  
incorporation or organization)

**000-54554**

(Commission File Number)

**45-1226465**

(I.R.S. Employer Identification  
Number)

**4093 Oceanside Boulevard, Suite B**

**Oceanside, California 92056**

(Address of Principal Executive Offices and Zip Code)

**(760) 295-7208**

(Issuer's telephone number)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- . Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events.**

On February 05, 2016, Therapeutic Solutions International, Inc. licensed certain intellectual property to MolecuVax, Inc., a wholly owned subsidiary of Therapeutic Solutions International, Inc.

Application No. 62/258,007 titled Exosome Mediated Innate and Adaptive Immune Stimulation for Treatment of Cancer was filed by TSI and the subject of a press release on February 08, 2016 has now been licensed to MolecuVax.

**Item 9.01 Financial Statements and Exhibits.**

Exhibit Index

(10.1) Exclusive Patent License Agreement between Therapeutic Solutions International, Inc., and MolecuVax, Inc.  
(99.1) Press release dated February 08, 2016, issued by Therapeutic Solutions International, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 08, 2016

THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.

By: /s/ Timothy Dixon

Timothy Dixon

Chief Executive Officer